About Meissa Vaccines

Meissa Vaccines develops live attenuated vaccine candidates against respiratory viruses, including RSV and SARS-CoV-2, using its proprietary AttenuBlock synthetic biology platform to optimize immune responses. These intranasal, adjuvant-free vaccines aim to prevent serious infections and generate durable immunity, addressing the critical need for effective protection against life-threatening respiratory diseases.

```xml <problem> Respiratory Syncytial Virus (RSV) and SARS-CoV-2 pose significant threats, especially to infants and the elderly, due to their ability to inhibit the immune system and cause severe respiratory illnesses. Current vaccines often require adjuvants and injections, which can present challenges for widespread adoption and may not fully replicate the body's natural immune response. There is a need for vaccines that can prevent infection and disease with a strong, durable immune response. </problem> <solution> Meissa Vaccines is developing live attenuated vaccine candidates against life-threatening respiratory viruses, including RSV and SARS-CoV-2, utilizing its proprietary AttenuBlock synthetic biology platform. The AttenuBlock platform optimizes the vaccine candidates to be safe and highly attenuated, inducing a superior immune response compared to natural infection. These vaccine candidates are designed for intranasal, adjuvant-free delivery, aiming to prevent infection and disease by inducing mucosal IgA and serum neutralizing antibodies for a multi-pronged, durable immune response. This needle-free approach seeks to improve vaccine accessibility and effectiveness against respiratory viruses. </solution> <features> - AttenuBlock synthetic biology platform for generating safe and highly attenuated vaccine candidates. - Intranasal delivery for needle-free administration and enhanced mucosal immunity. - Adjuvant-free formulation to minimize potential side effects. - Optimized to induce mucosal IgA and serum neutralizing antibodies. - Designed to prevent infection and disease, not just reduce symptom severity. - Vaccine candidates target RSV, SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV). </features> <target_audience> The primary target audience includes infants, toddlers, and the elderly, who are particularly vulnerable to severe complications from RSV and SARS-CoV-2 infections, as well as individuals seeking a more accessible and effective vaccination method. </target_audience> ```

What does Meissa Vaccines do?

Where is Meissa Vaccines located?

Meissa Vaccines is based in San Francisco, United States.

When was Meissa Vaccines founded?

Meissa Vaccines was founded in 2014.

How much funding has Meissa Vaccines raised?

Meissa Vaccines has raised 30000000.

Location

San Francisco, United States

Founded

2014

Funding

30000000

Employees

2 employees

Major Investors

Morningside Venture Investments

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Meissa Vaccines

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

meissavaccines.com 1K+

Crunchbase

Founded 2014 – San Francisco, United States

Funding

Estimated Funding

$20M+

Major Investors

Morningside Venture Investments

Team (<5)

No team information available.

Company Description

Problem

Respiratory Syncytial Virus (RSV) and SARS-CoV-2 pose significant threats, especially to infants and the elderly, due to their ability to inhibit the immune system and cause severe respiratory illnesses. Current vaccines often require adjuvants and injections, which can present challenges for widespread adoption and may not fully replicate the body's natural immune response. There is a need for vaccines that can prevent infection and disease with a strong, durable immune response.

Solution

Meissa Vaccines is developing live attenuated vaccine candidates against life-threatening respiratory viruses, including RSV and SARS-CoV-2, utilizing its proprietary AttenuBlock synthetic biology platform. The AttenuBlock platform optimizes the vaccine candidates to be safe and highly attenuated, inducing a superior immune response compared to natural infection. These vaccine candidates are designed for intranasal, adjuvant-free delivery, aiming to prevent infection and disease by inducing mucosal IgA and serum neutralizing antibodies for a multi-pronged, durable immune response. This needle-free approach seeks to improve vaccine accessibility and effectiveness against respiratory viruses.

Features

AttenuBlock synthetic biology platform for generating safe and highly attenuated vaccine candidates.

Intranasal delivery for needle-free administration and enhanced mucosal immunity.

Adjuvant-free formulation to minimize potential side effects.

Optimized to induce mucosal IgA and serum neutralizing antibodies.

Designed to prevent infection and disease, not just reduce symptom severity.

Vaccine candidates target RSV, SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Target Audience

The primary target audience includes infants, toddlers, and the elderly, who are particularly vulnerable to severe complications from RSV and SARS-CoV-2 infections, as well as individuals seeking a more accessible and effective vaccination method.